N@N

OPTR, OCN, ISPH, HEES, ICGE, BIOD Expected To Be Down After Next Earnings Releases

May 4, 2011 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Thursday, May 5th 2011 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and 6 Consecutive Days earnings reports. OPTIMER PHARMACEUTICALS INC (NASDAQ:OPTR), OCWEN FINANCIAL CORP (NYSE:OCN), INSPIRE PHARMACEUTICALS INC (NASDAQ:ISPH), H&E EQUIPMENT SERVICES INC (NASDAQ:HEES), INTERNET CAPITAL GROUP INC (NASDAQ:ICGE), BIODEL INC (NASDAQ:BIOD) are all expected to be Down After their earnings are released Thursday. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down After earnings are released Thursday:

     Symbol     Company                             # of Reports            Quarter     Release Time
     OPTR       OPTIMER PHARMACEUTICALS INC         6 Quarter               Q1          Before
     OCN        OCWEN FINANCIAL CORP                6 Quarter               Q1          Before
     ISPH       INSPIRE PHARMACEUTICALS INC         6 Quarter               Q1          Before
     HEES       H&E EQUIPMENT SERVICES INC          6 Quarter               Q1          Before
     ICGE       INTERNET CAPITAL GROUP INC          6 Quarter               Q1          Before
     BIOD       BIODEL INC                          6 Quarter               Q2          After

This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists.

OPTIMER PHARMACEUTICALS INC (NASDAQ:OPTR) - Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products worldwide. It develops products that treat gastrointestinal infections and related diseases. The companys two late-stage anti-infective product candidates include Fidaxomicin, the lead product candidate and an antibiotic for the treatment of clostridium difficile-infections, which completed two Phase III clinical trial; and Prulifloxacin, a prodrug in the fluoroquinolone class of antibiotics, which completed two Phase III trials for the treatment of infectious diarrhea, including travelers diarrhea. It also develops product candidates using its proprietary technology Optimer One-Pot Synthesis, a drug discovery platform and a computer-aided technology that enables the synthesis of carbohydrate-based compounds. In addition, the companys other pipeline product candidates consist of CEM-101 (OP-1068), a macrolide and ketolide antibiotic for the treatment of upper and lower respiratory tract infections; OPT-88, a disease-modifying intra-articular therapy for osteoarthritis; and OPT-822/OPT-821, a carbohydrate-based immunostimulant therapy for the treatment of metastatic breast cancer. Additionally, it licensed rights to Cempra Pharmaceuticals, Inc. to develop CEM-101; and granted rights to Optimer Biopharmaceuticals, Inc. to develop OPT-88 and OPT-822/821. Further, the company has collaborative agreements with Par Pharmaceuticals, Inc.; Nippon Shinyaku, Co., Ltd.; Memorial Sloan-Kettering Cancer Center; and Scripps Research Institute. Optimer Pharmaceuticals was founded in 1998 and is based in San Diego, California.

OCWEN FINANCIAL CORP (NYSE:OCN) - Ocwen Financial Corporation, through its subsidiaries, provides residential and commercial mortgage loan servicing, special servicing, and asset management services. The company operates in two segments, Ocwen Asset Management and Ocwen Solutions. The Ocwen Asset Management segment provides asset management and resolution services primarily to owners of subprime residential mortgages. This segment also involves in the trading and investing activities, including investments in subprime residual mortgage backed trading securities and whole loan purchase and securitization activities; subprime loan origination operations; and management of residential assets. The Ocwen Solutions segment offers mortgage services, including due diligence, valuation, real estate sales, default processing, property inspection and preservation, homeowner outreach, closing and title, and knowledge process outsourcing services. It also provides financial services, such as asset recovery and customer relationship management services to the financial services, consumer products, telecommunications, and utilities industries. In addition, this segment offers technology products, including REAL suite of applications, such as REALServicing, REALResolution, REALTransS, REALSynergy, and REALRemit, which support companys servicing business, as well as the servicing and origination businesses of external customers. The company has operations in the United States, Uruguay, and India. Ocwen Financial Corporation was founded in 1988 and is headquartered in West Palm Beach, Florida.

INSPIRE PHARMACEUTICALS INC (NASDAQ:ISPH) - Inspire Pharmaceuticals, Inc., a biopharmaceutical company, focuses on researching, developing, and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The company offers AzaSite, an azithromycin ophthalmic solution and topical anti-infective for the treatment of bacterial conjunctivitis; Elestat, an epinastine HCl ophthalmic solution and topical antihistamine for the prevention of ocular itching associated with allergic conjunctivitis; and Restasis, a cyclosporine ophthalmic emulsion for the treatment of dry eye disease. Its product candidates in clinical development include Denufosol tetrasodium for the treatment of cystic fibrosis, which is under phase III clinical trial; Prolacria for the treatment of dry eye disease, which is under phase III clinical trial; AzaSite for the treatment of blepharitis that is under phase II clinical trial; and Glaucoma product candidates, which are in phase I clinical trial. The company has an agreements with Allergan, Inc. to co-promote Elestat in the United States, as well as to develop and commercialize Restasis and Prolacria; a license agreement with InSite Vision Incorporated to commercialize AzaSite, as well as other topical anti-infective products containing azithromycin used in the treatment of human ocular or ophthalmic indications primarily in the United States and Canada; and a development, license, and supply agreement with Santen Pharmaceutical Co., Ltd. for the development of diquafosol tetrasodium for the therapeutic treatment of ocular surface diseases in Asia. Inspire Pharmaceuticals, Inc. was founded in 1993 and is based in Durham, North Carolina.

H&E EQUIPMENT SERVICES INC (NASDAQ:HEES) - H&E Equipment Services, Inc., an integrated equipment services company, provides heavy construction and industrial equipment in the United States. It rents, sells, and provides parts and service support for hi-lift or aerial platform equipment, cranes, earthmoving equipment, and industrial lift trucks. The company also sells new and used equipment and parts, as well as provides maintenance and repair services for the customers owned equipment. In addition, H&E Equipment Services offers ancillary equipment support activities, including transportation, hauling, parts shipping, and loss damage waivers. The company provides its services to industrial and commercial companies, construction contractors, manufacturers, public utilities, municipalities, and maintenance contractors, as well as for other industrial accounts. As of March 1, 2010, the company served approximately 29,500 customers through 66 full-service facilities across 24 states in the West Coast, Intermountain, Southwest, Gulf Coast, Southeast, and Mid-Atlantic regions of the United States. H&E Equipment Services was founded in 1961 and is headquartered in Baton Rouge, Louisiana.

INTERNET CAPITAL GROUP INC (NASDAQ:ICGE) - Internet Capital Group Inc. is a private equity and venture capital firm specializing in patient capital, growth capital, acquisitions, and mid and late venture investments in public and private companies. The firm seeks to invest in businesses involved in SaaS and technology enabled business process outsourcing, automating a complex workflow process, delivering comprehensive solutions including software, content data, and transactions, on-demand Internet software and services, Internet marketing or e-commerce, and service businesses including web enabled software platform. It also invests in business to business segment of the Internet industry. The firm typically invests between $10 million and $30 million and can evaluate deals upto $100 million. It seeks to invest in companies with minimum revenues $10 million, 20% to 30% CAGR, and positive EBITDA margin. The firm seeks to acquire a controlling and majority stake more than 50% or minority stake less than 20% in its portfolio companies. Internet Capital Group Inc. was founded in March, 1996 and is based in Wayne, Pennsylvania.

BIODEL INC (NASDAQ:BIOD) - Biodel Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes. The company develops its product candidates by utilizing its proprietary VIAdel technology that allows to study the interaction between peptide hormones and small molecules. Its product candidates include VIAject, an injectable formulation of recombinant human insulin, which has completed two pivotal Phase III clinical trials for the treatment of Type 1 and Type 2 diabetes; and VIAtab, a sublingual tablet formulation of insulin, which has completed Phase I clinical trial for Type 1 diabetes. The company was founded in 2003 and is headquartered in Danbury, Connecticut.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641